newsfilter
← Latest News
GlobeNewswire·

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended September 30, 2026

IMVT-1402 600 mg met the primary endpoint of ACR20 response at Week 28 (92.5% vs. 75.6% placebo, p=0.0139) in Period 2 (randomized withdrawal design following open-label lead-in) of the potentially registrational trial